China's WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to Merck for about $500 million. WuXi had ...
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody
PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications• NAYA aiming to ...
Future Market Insights41m
Thyroid Function Test Market in India Key Diagnostic Tool with Growing Demand Amidst Limited Access in Rural Areas
(Merck & Co., Inc.), Beckman Coulter, Inc., (Danaher), Siemens Healthcare GmbH and Abbott Laboratories. The report offers insights on the various strategies related to software development, market ...
Le Lézard43m
Prodeon Medical Announces Enrollment Completion for Expander-2 Pivotal Trial
Prodeon Medical, Inc., a medical device company developing a minimally invasive treatment for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia ...
Le Lézard17m
Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer
Iambic Therapeutics, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, announced that Michael Secora, Ph.D. will be its Chief ...
AFP3m
Merck Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
Merck, a leading science and technology company, announced the closing of the transaction to acquire HUB Organoids Holding ...
Patient Enrolment Completed for INSIGHT-003
Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches ...